KeyCorp Forecasts Strong Price Appreciation for Castle Biosciences (NASDAQ:CSTL) Stock

Castle Biosciences (NASDAQ:CSTL) had its price objective raised by KeyCorp from $35.00 to $40.00 in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock. KeyCorp‘s target price would suggest a potential upside of 23.00% from the stock’s previous close.

A number of other research analysts also recently issued reports on CSTL. Wall Street Zen upgraded Castle Biosciences from a “hold” rating to a “buy” rating in a research note on Sunday, November 1st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Castle Biosciences in a research report on Thursday, October 29th. BTIG Research boosted their price objective on Castle Biosciences from $40.00 to $44.00 and gave the company a “buy” rating in a research note on Monday, August 3rd. Robert W. Baird set a $36.00 price objective on Castle Biosciences in a research note on Friday, July 31st. Finally, Mizuho initiated coverage on Castle Biosciences in a report on Thursday, October 29th. They issued an “outperform” rating and a $60.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $44.88.

Castle Biosciences Price Performance

Shares of CSTL opened at $32.52 on Friday. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.04 and a quick ratio of 5.85. Castle Biosciences has a 1-year low of $17.72 and a 1-year high of $44.28. The stock has a market cap of $993.49 million, a PE ratio of -42.23 and a beta of 1.00. The firm has a fifty day moving average price of $34.25 and a 200 day moving average price of $28.53.

Castle Biosciences (NASDAQ:CSTL) last issued its quarterly earnings data on Thursday, November 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.22. Castle Biosciences had a negative return on equity of 4.92% and a negative net margin of 6.10%. The company had revenue of $101.95 million for the quarter, compared to analyst estimates of $92.77 million. As a group, sell-side analysts anticipate that Castle Biosciences will post -1.29 EPS for the current year.

Insider Activity

In other news, COO Kristen Oelschlager sold 4,153 shares of the company’s stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $35.95, for a total value of $149,300.35. Following the completion of the sale, the chief operating officer directly owned 13,356 shares of the company’s stock, valued at approximately $480,148.20. This represents a 23.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Tobin Juvenal sold 6,578 shares of the stock in a transaction dated Wednesday, October 28th. The stock was sold at an average price of $36.42, for a total transaction of $239,570.76. Following the sale, the insider owned 38,853 shares of the company’s stock, valued at $1,415,026.26. This trade represents a 14.48% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 126,184 shares of company stock valued at $4,324,506. Insiders own 6.10% of the company’s stock.

Institutional Trading of Castle Biosciences

Hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. acquired a new position in shares of Castle Biosciences in the second quarter valued at approximately $78,513,000. Jefferies Financial Group Inc. purchased a new stake in shares of Castle Biosciences during the second quarter worth approximately $15,440,000. AIGH Capital Management LLC purchased a new stake in shares of Castle Biosciences during the second quarter worth approximately $13,001,000. Renaissance Technologies LLC lifted its holdings in shares of Castle Biosciences by 8.1% during the first quarter. Renaissance Technologies LLC now owns 532,800 shares of the company’s stock worth $13,080,000 after purchasing an additional 39,700 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Castle Biosciences during the second quarter worth $7,912,000. 92.60% of the stock is owned by institutional investors and hedge funds.

Castle Biosciences News Roundup

Here are the key news stories impacting Castle Biosciences this week:

• Positive Sentiment: Q3 revenue rose 24% year over year to $102.9 million, beating analyst expectations, and the per-share loss of $0.13 was narrower than forecasts. Castle Biosciences Reports Third Quarter 2026 Results
• Positive Sentiment: Management raised 2026 revenue guidance to $385–$395 million from $365–$375 million. TissueCypher test report volume increased 47% year over year, with the company signaling 50%–52% volume growth for the full year. Revenue outlook and TissueCypher growth
• Positive Sentiment: KeyCorp raised its price target to $40 from $35 and maintained an Overweight rating, signaling potential upside in the firm’s view. KeyCorp recommendations
• Negative Sentiment: The company remains unprofitable: its quarterly loss widened from $0.02 per share a year earlier to $0.13, despite beating analyst estimates. Ongoing losses could weigh on sentiment alongside the otherwise strong growth and guidance update. Q3 loss and revenue results

Castle Biosciences Company Profile

Castle Biosciences, Inc is a molecular diagnostics company that develops and commercializes tests designed to help physicians diagnose cancer, assess disease risk and guide treatment decisions. The company focuses on conditions in which additional biological information can complement traditional pathology and clinical assessment.

Its portfolio includes DecisionDx-Melanoma, which helps evaluate the risk of metastatic recurrence in patients with cutaneous melanoma; DecisionDx-SCC, which assesses metastatic risk in cutaneous squamous cell carcinoma; and DecisionDx-UM, a test for determining metastatic risk in uveal melanoma.